Text Size

Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00205816
First received: September 16, 2005
Last updated: February 7, 2013
Last verified: February 2013
History of Changes

September 16, 2005
February 7, 2013
January 2004
November 2005   (final data collection date for primary outcome measure)
response
Same as current
Complete list of historical versions of study NCT00205816 on ClinicalTrials.gov Archive Site
  • micro response at subject level
  • micro response at pathogen level
  • clinical response at pathogen level
  • development of decreased susceptibility
Same as current
Not Provided
Not Provided
 
Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.
An Open-label, Noncomparative, Multi-center, Emergency Use Protocol Administering Tigecycline for the Treatment of Subjects With Infections Due to Resistant Pathogens.

The purpose of this study is to provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.

The secondary objective is to evaluate the safety and efficacy of tigecycline in the treatment of patients with selected serious infections where other treatment has not been successful.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Bacterial Infections
Drug: Tigecycline
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
26
November 2005
November 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects, greater than 8 years of age and a weight of more than 35 kilograms.
  • Patients with current bacterial infections who have not responded to other available appropriate antibiotic therapies.
  • Patient must give informed consent.

Exclusion Criteria:

  • Patients with an expected survival of less than 2 weeks.
  • Patients who have been designated as "Do Not Resuscitate".
  • Known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds related to this class of antibacterial agents.
  • Pregnant women or nursing mothers.
Both
8 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Germany,   Poland
 
NCT00205816
3074A1-310
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP